Longevity Lab Report

Comparison

The Executive Screening Stack, Graded: What to Buy, What to Skip

Clinics sell the stack as one product at one price. Graded piece by piece, it comes apart: the cheapest tests carry the evidence, and the most expensive one carries the caveats.

Saved articles

Ask ChatGPT about this article ↗

Copy the prompt, then paste it into ChatGPT to explore the findings and sources.

Open ChatGPT ↗

The findings

Of the five tests in a typical executive screening stack, two earn their price: a coronary calcium scan (B) and a DEXA body composition scan (B). A glucose monitor experiment is defensible (C-). AI plaque analysis (C-) and whole-body MRI (D+) sell detection the evidence does not support at a screening cadence.

The executive physical has become a product. Clinics in London, Stockholm, Singapore, and Los Angeles sell a day of testing as a single package: scans, blood panels, imaging, and a report, at prices that run from a few hundred dollars to $8,500 at Human Longevity Inc in the United States and £7,995 at the top tier in London. The marketing promise is early detection, stated broadly. What the package price hides is that the components are not equals. Some of these tests rest on decades of outcome data and cost less than the parking at the clinic. One of them flags something in roughly a third of the people who take it and cannot tell most of them what the flag means.

This page grades the stack the way the library grades everything else: one component at a time, at the price and cadence it is actually sold, against the evidence for screening people who feel well. The verdict up front is that the stack is worth buying in pieces and not as a bundle. The two cheapest components carry the strongest evidence. The most expensive component carries the weakest.

The graded stack

ComponentGradeWhat it costsCadence the evidence supportsThe cost after the test
Coronary artery calcium scanB$50 to $400 self-pay, commonly $75 to $250One decision scan; a zero score is commonly rescanned at 3 to 7 yearsA high score starts a statin conversation and possibly further cardiac testing
DEXA body composition scanBTens of dollars to about $150; BodySpec lists $40 to $60Quarterly at the fastest for composition changeAlmost none; the result is a number you train against
Continuous glucose monitor, no diabetesC-About $89 a month over the counter (Stelo, Lingo)A 2 to 4 week experiment, not a subscriptionA year of wearing one runs about $1,070 for data with no agreed action thresholds
CCTA with AI plaque analysisC-The scan, plus about $1,021 for the AI analysis under its billing codeNo rescan cadence the evidence supportsIncidental findings and a plaque number with no validated treatment pathway in asymptomatic people
Whole-body MRID+$2,499 at Prenuvo list price; Ezra lists $499 to $999Annual is the vendor's claim, not a studied cadenceRoughly 1 in 3 scans flags something; the follow-up imaging, biopsies, and specialist visits are unpriced and yours

Prices are US self-pay figures from the records as reviewed in November 2026; the component records carry the sources and the full reasoning behind each grade.

Start with the calcium scan

The coronary artery calcium scan is the stack's strongest component and nearly its cheapest. It is a short CT scan that measures calcified plaque in the heart's arteries and returns a number, the Agatston score, that predicts heart attack and stroke risk well enough to change treatment decisions. A score of zero in a middle-aged adult is genuinely reassuring, and a high score is one of the clearest signals in preventive cardiology that a statin conversation should start years earlier than cholesterol numbers alone would suggest. The major cardiology guidelines give it a defined role for exactly the person buying an executive physical: an adult at intermediate risk whose treatment decision is uncertain.

Its limits are printed on the record. It involves a small radiation dose. It sees calcified plaque, not the soft plaque that can also rupture. And it is a decision scan, not a subscription: once it has answered the statin question, repeating it annually adds cost and radiation without adding decisions. That is the pattern the rest of the stack keeps breaking.

DEXA: the honest second

A DEXA body composition scan earns the same grade for a different reason: it answers a smaller question accurately and cheaply. It measures body fat, lean mass, and bone density in a few minutes, and for someone training or losing weight it replaces guesswork about whether the loss is fat or muscle with a measurement. At $40 to $150 it is priced like a lab test, and its cadence is honest: body composition changes slowly enough that quarterly is the fastest rescan that can show anything real. It detects no diseases and prevents nothing, and it does not claim to. In a stack sold on detection claims, the test that makes none is the easiest to grade kindly.

The glucose monitor: an experiment, not a membership

A continuous glucose monitor on a person without diabetes is the stack's most interesting component and its most oversold. Worn for two to four weeks, it teaches something real: which of your meals spike your glucose, how sleep and training move the line, how your body handles the foods you actually eat. That experiment is worth roughly one sensor's price. What the evidence does not support is the standing subscription. There are no agreed action thresholds for glucose patterns in people without diabetes, no trial showing that wearing one continuously improves outcomes in this population, and a year's supply runs about $1,070 to produce data that mostly confirms the first month's lessons. Grade C- is the grade for a good experiment sold as a habit.

CCTA with AI plaque analysis: a sharper picture of an unanswered question

Coronary CT angiography with AI plaque quantification produces the most detailed picture in the stack: not just whether plaque exists, but how much, and of what type. In symptomatic patients, that picture guides real decisions. In a person who feels well and has already had a calcium scan, the picture mostly raises questions it cannot settle. There is no validated treatment pathway keyed to an AI plaque number in asymptomatic people, no rescan cadence the evidence supports, and the AI analysis itself bills at about $1,021 under its 2026 Medicare code, on top of the scan. Incidental findings, on the lungs, the thyroid, the spine, arrive with the territory and start cascades of their own. The technology is impressive and the grade is C-, because a screening test is graded on what a healthy person should do with its result, and here the honest answer is: usually, nothing different.

Whole-body MRI: the headline product, the weakest grade

Whole-body MRI is the component the packages lead with, and it grades last. The pitch is a single scan that looks for cancer and disease across the body, priced at $2,499 at the best-known US provider and sold on an annual cadence. The problems are structural. Roughly a third of scans flag something, and most flags are benign or indeterminate, which converts a screening visit into months of follow-up imaging, specialist appointments, and occasionally biopsies, none of it priced into the package. There is no randomized evidence that scanning healthy people head to toe reduces mortality, and the detection claims in the marketing carry no false-positive rates beside them. One US hospital system's own executive-health FAQ argues against full-body scans for exactly this reason, which is a useful measure of where the clinical consensus sits relative to the sales copy. A reader with a specific concern, a family history, a symptom, should scan that concern with their clinician's direction. A reader buying certainty by the body-part is buying the cascade, not the certainty. Grade D+.

The foundation the packages skip

Underneath every stack sits the screening that guidelines actually recommend, and it is worth noticing how little of it appears in the marketing. Age-appropriate cancer screening with outcome evidence behind it, blood pressure, lipids, a diabetes test for adults in the risk window, and the unglamorous vaccinations and examinations that carry mortality data: this is the foundation, it is mostly cheap, and clinics that sell premium stacks generally assume it rather than feature it. UCHealth's executive programme is the honorable exception in the market this page reviewed, gating even its calcium scoring by age and sex in line with the guidelines. If a package's brochure leads with the MRI and never mentions the foundation, the brochure is telling you what the product is.

What the stack sells that grading does not support

Three patterns repeat across the market and none of them survives the records. The first is the marker panel: dozens of blood markers, including cancer markers such as CA-125, bundled into base packages for people without symptoms, where a marker's false-positive rate in a low-risk population guarantees abnormal results that mean nothing. The second is cadence inflation: annual everything, because the subscription is the business model, where the evidence supports a decision scan once, a composition scan quarterly at most, and a glucose experiment measured in weeks. The third is detection language without denominators: lesions found, diseases caught early, a pledge denominated in dollars, none of it accompanied by the false-positive rate or the follow-up cost that a third of buyers will meet. A grade is a denominator. It asks what the test found, in how many people, and what happened next, and it is the question the brochures are built to avoid.

Counting the real price

The package price is the smallest honest number in this market. Add the time: a full screening day, then the follow-up appointments the findings generate. Add the cascade: the flagged thyroid nodule becomes an ultrasound, a biopsy, a surgical consult. Add the rescan treadmill the annual cadence creates. Against that accounting, the graded core of the stack is almost embarrassingly affordable: a calcium scan at $75 to $250 once, a DEXA at $40 to $60 a few times a year if you are training seriously, and a month of glucose monitoring at $89 if you run it as the experiment it is. Everything above that line should have to argue for itself, component by component, against its record. That argument is what the grades above are for.

Method and sources

Each component's grade, price range, and cadence judgment comes from its library record, which carries the underlying sources: the guidelines and outcome literature for the calcium scan, the CMS 2026 fee schedule for the AI analysis code, provider list prices checked in November 2026 for the imaging components, and the trial and review literature for glucose monitoring in people without diabetes. The market description draws on the executive-health packages publicly listed by providers in the US, the UK, Singapore, and Sweden as reviewed in November 2026, including their published prices and claims. Screening decisions for a specific person belong with their clinician, who knows the history a brochure cannot.

Screening tests mentioned

Grades are research summaries, not medical advice. Decisions about your own health belong with your clinician.

Keep exploring

View all

Science & aging / Analysis

What anti-aging treatments can change

Bryan Johnson named five limits of today’s anti-aging technology. We examine the evidence behind each one.

Daniel Cole

The weekly newsletter

Keep up with what’s changing.

New research, useful tools, and the people shaping health and longevity. Selected and explained in one email.

See what you’ll receive ↗

Free. Confirm your email to subscribe. Unsubscribe anytime.